会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Preparation for control of T-system of immunity and method for producing
same
    • 免疫T系统的控制准备及其制备方法
    • US4377511A
    • 1983-03-22
    • US203347
    • 1980-11-03
    • Jury M. LopukhinRem V. PetrovVitaly Y. ArionJury N. BreusovTatyana V. GladyshevaIrina V. SaninaVasily V. LebedevSerafima S. KirzonEvgeny F. Ivanushkin
    • Jury M. LopukhinRem V. PetrovVitaly Y. ArionJury N. BreusovTatyana V. GladyshevaIrina V. SaninaVasily V. LebedevSerafima S. KirzonEvgeny F. Ivanushkin
    • A61K35/24A61K35/26A61K38/00A61K38/22A61P7/00A61P35/00A61P37/00C07G7/00A61K37/00
    • A61K35/26Y10S530/837
    • The present invention relates to immunopharmacology and, more specifically, to a preparation controlling the T-system of immunity and to a method for producing the same.The preparation controlling the T-system of immunity is characterized by its content as the active principle, peptides with a molecular mass of from 1,500 to 6,000 Dalton having absorption maximum in UV-light at 280 and 275 nm and electrophoretic mobility in a polyacrylamide gel relative to bromophenol blue: 0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930.The method for producing the preparation according to the present invention comprises homogenization of a tissue of thymus gland in a solution of sodium chloride; the homogenizate is kept for 12-16 hours at a temperature of from 2.degree. to 6.degree. C., the residue is removed, thermolabile proteins are removed from the solution, peptides and proteins are precipitated and then dissolved and peptides are salted-out from the solution successively in three stages, the residue of peptides is removed, ultrafiltered through a membrane with a rated retention limit relative to globular proteins of from 12,000 to 30,000, the ultrafiltrate is gel-chromatographed to isolate peptides with a molecular mass of from 1,500 to 6,000 Dalton, desalted and lyophilized.This preparation is used for the treatment of primary and secondary immunodeficient states, diseases caused by malignant neoplasms, psoriasis and other pathological states.
    • 本发明涉及免疫药理学,更具体地涉及控制免疫T系统的制剂及其制备方法。 控制免疫T系统的制剂的特征在于其作为活性成分的含量,分子量为1,500至6,000道尔顿的肽在280和275nm的紫外光下具有最大吸收和聚丙烯酰胺凝胶相对电泳迁移率 至溴酚蓝:0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930。 根据本发明的制备方法包括在氯化钠溶液中均匀化胸腺组织; 匀浆在2℃至6℃的温度下保持12-16小时,除去残余物,从溶液中除去不溶性蛋白质,使肽和蛋白质沉淀,然后溶解,将肽从 该溶液依次分三个步骤,除去肽残余物,通过相对于球状蛋白的保留极限为12,000至30,000的膜进行超滤,将超滤液凝胶色谱分离以分离分子量为1,500至 6,000道尔顿,脱盐并冻干。 该制剂用于治疗原发性和继发性免疫缺陷状态,由恶性肿瘤引起的疾病,牛皮癣和其他病理状态。